Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

News Conference News AHA 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

November 14, 2025

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

News Conference News AHA 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

November 18, 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

November 14, 2024

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

News Conference News AHA 2023

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

November 14, 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

November 13, 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

November 11, 2023

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

News Conference News AHA 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

November 05, 2022

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

November 17, 2021

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

November 22, 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

November 17, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

November 16, 2019

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

November 13, 2018

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

News Conference News AHA 2018

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Michael O'Riordan

November 11, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.